Norepinephrine transporter −3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to investigate a possible association between norepinephrine genes and cardiovascular side effects of the Osmotic Controlled-Release Oral Delivery System–methylphenidate (OROS-MPH) in Korean children with attention-deficit/hyperactivity disorder (ADHD). One hundred and one children with ADHD (8.7 ± 1.7 years) were recruited from child psychiatric centers at six university hospitals in South Korea. All participants were drug-naive ADHD children treated with OROS-MPH for 12 weeks. During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects. Resting heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) were examined before and after treatment. The percentage change score (post-treatment – pretreatment/pretreatment × 100) of each parameter was calculated. Genotyping of SLC6A2 −3081(A/T) and G1287A, and alpha-2A-adrenergic receptor (ADRA2A) MspI and DraI polymorphisms was performed. Clinically significant changes were not found in cardiovascular monitoring during the course of treatment. An increase of HR after OROS-MPH treatment was found to be statistically significant ( t = 3.54, p = 0.001). Changes in SBP and DBP were not significant and no specific change was found in the ECGs. However, an additive regression analysis demonstrated a significant association between SLC6A2 −3081(A/T) and percentage change in HR post-treatment ( p = 0.01) after controlling for age, gender, dosage of MPH and response and baseline pulse rate. Children with ADHD having the T/T genotype of SLC6A2 showed a 12.5% increase in HR compared to baseline, whereas children with the A/T or A/A genotype showed a 3.5% and 2.5% increase after OROS-MPH treatment, respectively. There was also a significant association between the ADRA2A MspI genotype and percentage change of DBP post-treatment after controlling for age, gender, dosage of MPH and response and baseline DBP ( p = 0.009). Children with ADHD having the C/C genotype of ADRA2A MspI showed an 18.5% increase in DBP compared to baseline, but children with the G/G or G/C genotype showed a 0.2% decrease after OROS-MPH treatment. The overall cardiovascular effects of OROS-MPH were modest. However, our findings show a positive association between norepinephrine-related gene polymorphisms and cardiovascular response induced by MPH in Korean children with ADHD. Consideration must be given to such children oradults with specific norepinephrine-related genotypes, especially if they show significant changes in HR or DBP after OROS-MPH administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677 · cited 1×
“NET inhibition also increases the responsiveness to vasoactive medications and attenuates the response to sympathetic stimuli (Strempel et al., 2008; Tank et al., 2003).”
BackgroundBerridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F. T., Kelley, A. E., Schmeichel, B., Hamilton, C., & Spencer, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.022 · Cited by 617 · cited 1×
“Another study reported that low doses of MPH produced a maximal increase in NE concentrations of approximately 280% above baseline, substantially larger than that produced for dopamine under the same dose (Berridge et al., 2006).”
BackgroundOrthostatic Intolerance and Tachycardia Associated with Norepinephrine-Transporter Deficiency
Shannon, J. R., Flattem, N. L., Jordan, J., Jacob, G., Black, B. K., Biaggioni, I., Blakely, R. D., & Robertson, D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420803 · Cited by 594 · cited 2×
“Evidence from many animal studies of cardiovascular response shows that NET inhibition by drugs or gene knockout/knockdown can evoke variable HR changes in diverse situations (Carson et al., 2002; Keller et al., 2004; Mayer et al., 2006; Schroeder et al., 2004; Shannon et al., 2000; Wakamatsu et al., 2009).”
BackgroundMTA Cooperative Group (2004) · Pediatrics · doi:10.1542/peds.113.4.754 · Cited by 589
Pharmacogenetics of Methylphenidate Response in Preschoolers With ADHD
McGOUGH, J., McCRACKEN, J., SWANSON, J., RIDDLE, M., KOLLINS, S., GREENHILL, L., ABIKOFF, H., DAVIES, M., CHUANG, S., WIGAL, T., et al. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000235083.40285.08 · Cited by 126 · cited 1×
“Moreover, the few pharmacogenetic studies of the side effects ofMPHhave usually dealt with behavioral and somatic aspects including appetite suppression, insomnia, tic and emotional change (Gruber et al., 2009; Leddy et al., 2009; McGough et al., 2006).”
BackgroundAbikoff, H. B., Vitiello, B., Riddle, M. A., Cunningham, C., Greenhill, L. L., Swanson, J. M., Chuang, S. Z., Davies, M., Kastelic, E., Wigal, S. B., et al. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0068 · Cited by 118 · cited 1×
“Clinical trials across diverse age groups show that MPH is effective in preschool children, school-aged children, adolescents, and adults (Anon 1999; Abikoff et al., 2007; Ghuman et al., 2009; Ramos-Quiroga et al., 2009).”
BackgroundKobel, M., Bechtel, N., Weber, P., Specht, K., Klarhöfer, M., Scheffler, K., Opwis, K., & Penner, I.-K. (2009) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2008.10.008 · Cited by 104
Methylphenidate Increases Cortical Excitability via Activation of Alpha-2 Noradrenergic Receptors
Andrews, G. D., & Lavin, A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300818 · Cited by 101 · cited 1×
“A recent study of the mechanismof actiondemonstrated that anMPH-induced increase in cortical cell excitability is mediated by the activation of both dopamine and norepinephrine receptors in cortical areas, especially in the prefrontal cortex (Andrews and Lavin, 2006).”
BackgroundWang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y.-J., Cho, S. C., Kim, B. N., Ahn, D. H., Marquez-Caraveo, M. E., Gao, H., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601057767 · Cited by 84 · cited 1×
“The cardiovascular effects of other stimulant (amphetamine) or nonstimulant drugs (atomoxetine) for ADHD treatment have mostly been associated with their presynaptic and postsynaptic sympathomimetic noradrenergic apparati (Findling et al., 2001; Wang et al., 2007; Winterstein et al., 2009).”
BackgroundSelf-citation
Cited by
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
Ching, C., Eslick, G. D., & Poulton, A. S. (2019) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2019.0905 · Cited by 70
Yuan, D., Zhang, M., Huang, Y., Wang, X., Jiao, J., & Huang, Y. (2021) · Medicine · doi:10.1097/md.0000000000027858 · Cited by 21
Joensen, B., Meyer, M., & Aagaard, L. (2017) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_16_161 · Cited by 14
Metadata
- Authors
- Cho, S.-C., Kim, B.-N., Cummins, T. D., Kim, J.-W., & Bellgrove, M. A.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-05-31
- Volume
- 26
- Issue
- 3
- Pages
- 380-389
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2145944079
- Cited by
- 19
- References
- 12
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Norepinephrine transporter −3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. https://app.cochat.ai/papers/10.1177/0269881111405356
- The paper
- Cho, S.-C., Kim, B.-N., Cummins, T. D., Kim, J.-W., & Bellgrove, M. A. (2012). Norepinephrine transporter −3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. Journal of Psychopharmacology. https://doi.org/10.1177/0269881111405356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.